We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Therapeuticsmd Inc
45 own
77 watching
Current Price
$1.15
$0.07
(6.48%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
23.91M
52-Week High
2.75
52-Week Low
0.69999999
Average Volume
0.13M
Dividend Yield
--
P/E Ratio
--
Market Capitalization23.91M52-Week High2.7552-Week Low0.69999999Average Volume0.13MDividend Yield--P/E Ratio--What does the Therapeuticsmd Inc do?
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
Read More
How much money does Therapeuticsmd Inc make?
News & Events about Therapeuticsmd Inc.
Ticker Report
2years ago
TherapeuticsMD, Inc. (NASDAQ:TXMD Get Rating) was the target of a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 664,500 shares, a growth of 65.7% from the June 30th total of 401,000 shares. Based on an average trading ...
Zolmax
2years ago
Cantor Fitzgerald reaffirmed their neutral rating on shares of TherapeuticsMD (NASDAQ:TXMD Get Rating) in a research report released on Wednesday, Marketbeat.com reports. Separately, HC Wainwright cut shares of TherapeuticsMD from a buy rating to a neutral rating in a research report on Tuesday, ...
Ticker Report
2years ago
TherapeuticsMD (NASDAQ:TXMD Get Rating)s stock had its neutral rating restated by Cantor Fitzgerald in a report released on Wednesday, Marketbeat Ratings reports. Separately, HC Wainwright cut TherapeuticsMD from a buy rating to a neutral ...
Globe Newswire
2years ago
NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of TherapeuticsMD, Inc. (NASDAQ: TXMD) breached their fiduciary duties or violated the federal securities...
PR Newswire
2years ago
Investor Alert - The M&A Class Action Firm Announces an Investigation of TherapeuticsMD, Inc. - TXMD Investor Alert - The M&A Class Action Firm Announces an Investigation of TherapeuticsMD, Inc. - TXMD PR Newswire NEW YORK, June 1, 2022 NEW YORK, June 1, 2022 /PRNewswire/ -- Juan...
Frequently Asked Questions
Frequently Asked Questions
What is Therapeuticsmd Inc share price today?
Can Indians buy Therapeuticsmd Inc shares?
How can I buy Therapeuticsmd Inc shares from India?
Can Fractional shares of Therapeuticsmd Inc be purchased?
What are the documents required to start investing in Therapeuticsmd Inc stocks?
What is today’s traded volume of Therapeuticsmd Inc?
What is today’s market capitalisation of Therapeuticsmd Inc?
What is the 52-Week High and Low Range of Therapeuticsmd Inc?
What percentage is Therapeuticsmd Inc down from its 52-Week High?
What percentage is Therapeuticsmd Inc up from its 52-Week Low?
Current Price
$1.15
$0.07
(6.48%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.